Flex Pharma's cramp study fails, shares plunge; FDA makes Egalet wait on pain drug
Shares of Flex Pharma $FLKS took a nasty hit yesterday as the biotech tried to explain away a preliminary conclusion that their lead drug, …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
